Eculizumab Therapy Leads to Rapid Resolution of Thrombocytopenia in Atypical Hemolytic Uremic Syndrome

Figure 1

Rapid resolution of thrombocytopenia with eculizumab therapy for aHUS. In Cases 1–4 of aHUS (panels a–d), the platelet counts began to steadily increase within 3 days, normalizing by day 7 following initiation of eculizumab therapy. Such rapid and steady increase in the platelet count did not occur in three cases when they were treated with plasma exchange. The dashed lines mark the lower limit of normal platelet counts.

(a) Case  1

(b) Case  2

(c) Case  3

(d) Case  4